Tags

Type your tag names separated by a space and hit enter

Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia.
Emerg Infect Dis. 2016 09; 22(9):1554-61.EI

Abstract

We explored the feasibility of collecting convalescent plasma for passive immunotherapy of Middle East respiratory syndrome coronavirus (MERS-CoV) infection by using ELISA to screen serum samples from 443 potential plasma donors: 196 patients with suspected or laboratory-confirmed MERS-CoV infection, 230 healthcare workers, and 17 household contacts exposed to MERS-CoV. ELISA-reactive samples were further tested by indirect fluorescent antibody and microneutralization assays. Of the 443 tested samples, 12 (2.7%) had a reactive ELISA result, and 9 of the 12 had reactive indirect fluorescent antibody and microneutralization assay titers. Undertaking clinical trials of convalescent plasma for passive immunotherapy of MERS-CoV infection may be feasible, but such trials would be challenging because of the small pool of potential donors with sufficiently high antibody titers. Alternative strategies to identify convalescent plasma donors with adequate antibody titers should be explored, including the sampling of serum from patients with more severe disease and sampling at earlier points during illness.

Links

Publisher Full Text
ncbi.nlm.nih.gov
doi.org
PMC Free PDF

Authors

Arabi YM
No affiliation info available
Hajeer AH
No affiliation info available
Luke T
No affiliation info available
Raviprakash K
No affiliation info available
Balkhy H
No affiliation info available
Johani S
No affiliation info available
Al-Dawood A
No affiliation info available
Al-Qahtani S
No affiliation info available
Al-Omari A
No affiliation info available
Al-Hameed F
No affiliation info available
Hayden FG
No affiliation info available
Fowler R
No affiliation info available
Bouchama A
No affiliation info available
Shindo N
No affiliation info available
Al-Khairy K
No affiliation info available
Carson G
No affiliation info available
Taha Y
No affiliation info available
Sadat M
No affiliation info available
Alahmadi M
No affiliation info available

MeSH

Antibodies, NeutralizingAntibodies, ViralCoronavirus InfectionsEnzyme-Linked Immunosorbent AssayHealth PersonnelHumansImmunoglobulin GImmunotherapyMiddle East Respiratory Syndrome CoronavirusNeutralization TestsPlasmaRNA, ViralReverse Transcriptase Polymerase Chain ReactionSaudi Arabia

Pub Type(s)

Journal Article

Language

eng

PubMed ID

27532807

Clinical Trial Links

Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection
Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure
Plasma Therapy of COVID-19 in Severely Ill Patients
Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults
Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia
Convalescent Plasma for COVID-19 Close Contacts
Feasibility Study of Anti-SARS-CoV-2 Plasma Transfusions in COVID-19 Patients With SRD
Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 Patients
Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection
Administration of Anti-SARS-CoV-2 Convalescent Plasma in Hospitalized, Non-ICU Patients With COVID-19

Citation

Arabi, Yaseen M., et al. "Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia." Emerging Infectious Diseases, vol. 22, no. 9, 2016, pp. 1554-61.
Arabi YM, Hajeer AH, Luke T, et al. Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia. Emerg Infect Dis. 2016;22(9):1554-61.
Arabi, Y. M., Hajeer, A. H., Luke, T., Raviprakash, K., Balkhy, H., Johani, S., Al-Dawood, A., Al-Qahtani, S., Al-Omari, A., Al-Hameed, F., Hayden, F. G., Fowler, R., Bouchama, A., Shindo, N., Al-Khairy, K., Carson, G., Taha, Y., Sadat, M., & Alahmadi, M. (2016). Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia. Emerging Infectious Diseases, 22(9), 1554-61. https://doi.org/10.3201/eid2209.151164
Arabi YM, et al. Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia. Emerg Infect Dis. 2016;22(9):1554-61. PubMed PMID: 27532807.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia. AU - Arabi,Yaseen M, AU - Hajeer,Ali H, AU - Luke,Thomas, AU - Raviprakash,Kanakatte, AU - Balkhy,Hanan, AU - Johani,Sameera, AU - Al-Dawood,Abdulaziz, AU - Al-Qahtani,Saad, AU - Al-Omari,Awad, AU - Al-Hameed,Fahad, AU - Hayden,Frederick G, AU - Fowler,Robert, AU - Bouchama,Abderrezak, AU - Shindo,Nahoko, AU - Al-Khairy,Khalid, AU - Carson,Gail, AU - Taha,Yusri, AU - Sadat,Musharaf, AU - Alahmadi,Mashail, PY - 2016/8/18/entrez PY - 2016/8/18/pubmed PY - 2018/2/2/medline KW - ELISA KW - IFA KW - MERS KW - MERS-CoV KW - Middle East respiratory syndrome KW - Middle East respiratory syndrome coronavirus KW - Saudi Arabia KW - antibody titers KW - convalescent phase KW - convalescent plasma KW - convalescent-phase plasma KW - feasibility study KW - humans KW - immunotherapy KW - indirect immunofluorescent antibody assay KW - intensive care KW - microneutralization KW - neutralizing antibodies KW - respiratory infections KW - seroreactive KW - viruses SP - 1554 EP - 61 JF - Emerging infectious diseases JO - Emerg Infect Dis VL - 22 IS - 9 N2 - We explored the feasibility of collecting convalescent plasma for passive immunotherapy of Middle East respiratory syndrome coronavirus (MERS-CoV) infection by using ELISA to screen serum samples from 443 potential plasma donors: 196 patients with suspected or laboratory-confirmed MERS-CoV infection, 230 healthcare workers, and 17 household contacts exposed to MERS-CoV. ELISA-reactive samples were further tested by indirect fluorescent antibody and microneutralization assays. Of the 443 tested samples, 12 (2.7%) had a reactive ELISA result, and 9 of the 12 had reactive indirect fluorescent antibody and microneutralization assay titers. Undertaking clinical trials of convalescent plasma for passive immunotherapy of MERS-CoV infection may be feasible, but such trials would be challenging because of the small pool of potential donors with sufficiently high antibody titers. Alternative strategies to identify convalescent plasma donors with adequate antibody titers should be explored, including the sampling of serum from patients with more severe disease and sampling at earlier points during illness. SN - 1080-6059 UR - https://www.unboundmedicine.com/medline/citation/27532807/full_citation L2 - https://doi.org/10.3201/eid2209.151164 DB - PRIME DP - Unbound Medicine ER -